A possible association of the norepinephrine transporter gene in the development of heroin dependence in Han Chinese

Pharmacogenetics and Genomics

Volumn 21, Issue 4, 2011, Pages 197-205

  Yeh, Yi Wei ^a   Lu, Ru Band ^c   Tao, Pao Luh ^b   Shih, Mei Chen ^a   Huang, San Yuan ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Heroin dependence; Norepinephrine transporter gene personality trait; Polymorphism; SLC6A2

Indexed keywords

NORADRENALIN TRANSPORTER;

ADULT; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERSONALITY; PRIORITY JOURNAL; QUESTIONNAIRE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79955469901     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833ef418     Document Type: Article

References (52)

1. Hall W, Doran C, Degenhardt L, Shepard D. Illicit opioid use. In: Jamison D, Breman J, Measham A, Alleyne G, GClaeson M, Evans D, et al. editors. Disease control priorities in developing countries. New York: Oxford University Press; 2006. pp. 907-932.
2. Tsuang MT, Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, et al. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3372 twin pairs. Am J Med Genet 1996; 67:473-477.
3. Tsuang MT, Lyons MJ, Meyer JM, Doyle T, Eisen SA, Goldberg J, et al. Cooccurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 1998; 55:967-972. (Pubitemid 28506837)
4. Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 2003; 160:687-695. (Pubitemid 41079601)
5. Wang X, Cen X, Lu L. Noradrenaline in the bed nucleus of the stria terminalis is critical for stress-induced reactivation of morphine-conditioned place preference in rats. Eur J Pharmacol 2001; 432:153-161. (Pubitemid 34003596)
6. Shaham Y, Highfield D, Delfs J, Leung S, Stewart J. Clonidine blocks stressinduced reinstatement of heroin seeking in rats: an effect independent of locus coeruleus noradrenergic neurons. Eur J Neurosci 2000; 12:292-302. (Pubitemid 30068434)
7. Goodman A. Neurobiology of addiction. An integrative review. Biochem Pharmacol 2008; 75:266-322. (Pubitemid 350245486)
8. Banna KM, Back SE, Do P, See RE. Yohimbine stress potentiates conditioned cue-induced reinstatement of heroin-seeking in rats. Behav Brain Res 2010; 208:144-148.
9. Ventura R, Alcaro A, Puglisi-Allegra S. Prefrontal cortical norepinephrine release is critical for morphine-induced reward, reinstatement and dopamine release in the nucleus accumbens. Cereb Cortex 2005; 15:1877-1886. (Pubitemid 41628329)
10. Auclair A, Drouin C, Cotecchia S, Glowinski J, Tassin JP. 5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur J Neurosci 2004; 20:3073-3084. (Pubitemid 40007302)
11. Olson VG, Heusner CL, Bland RJ, During MJ, Weinshenker D, Palmiter RD. Role of noradrenergic signaling by the nucleus tractus solitarius in mediating opiate reward. Science 2006; 311:1017-1020. (Pubitemid 43271731)
12. Weinshenker D, Schroeder JP. There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology 2007; 32:1433-1451. (Pubitemid 46920149)
13. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005; 57:1-26. (Pubitemid 40283968)
14. Bohn LM, Xu F, Gainetdinov RR, Caron MG. Potentiated opioid analgesia in norepinephrine transporter knock-out mice. J Neurosci 2000; 20:9040-9045. (Pubitemid 32042905)
15. Kim H, Lee H, Rowan J, Brahim J, Dionne RA. Genetic polymorphisms in monoamine neurotransmitter systems show only weak association with acute post-surgical pain in humans. Mol Pain 2006; 2:24.
16. Hahn MK, Blackford JU, Haman K, Mazei-Robison M, English BA, Prasad HC, et al. Multivariate permutation analysis associates multiple polymorphisms with subphenotypes of major depression. Genes Brain Behav 2008; 7:487-495. (Pubitemid 351590936)
17. Inoue K, Itoh K, Yoshida K, Shimizu T, Suzuki T. Positive association between T-182C polymorphism in the norepinephrine transporter gene and susceptibility to major depressive disorder in a Japanese population. Neuropsychobiology 2004; 50:301-304. (Pubitemid 39482669)
18. Chang CC, Lu RB, Chen CL, Chu CM, Chang HA, Huang CC, et al. Lack of association between the norepinephrine transporter gene and major depression in a Han Chinese population. J Psychiatry Neurosci 2007; 32:121-128.
19. Chang CC, Lu RB, Ma KH, Chang HA, Chen CL, Huang CC, et al. Association study of the norepinephrine transporter gene polymorphisms and bipolar disorder in Han Chinese population. World J Biol Psychiatry 2007; 8:188-195.
20. Szoke A, Schurhoff F, Meary A, Mathieu F, Chevalier F, Trandafir A, et al. Lack of influence of COMT and NET genes variants on executive functions in schizophrenic and bipolar patients, their first-degree relatives and controls. Am J Med Genet B Neuropsychiatr Genet 2006; 141:504-512. (Pubitemid 44024445)
21. Lee YJ, Hohoff C, Domschke K, Sand P, Kuhlenbaumer G, Schirmacher A, et al. Norepinephrine transporter (NET) promoter and 50-UTR polymorphisms: association analysis in panic disorder. Neurosci Lett 2005; 377:40-43. (Pubitemid 40255636)
22. Kim CH, Hahn MK, Joung Y, Anderson SL, Steele AH, Mazei-Robinson MS, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci U S A 2006; 103:19164-19169. (Pubitemid 350002844)
23. Barr CL, Kroft J, Feng Y, Wigg K, Roberts W, Malone M, et al. The norepinephrine transporter gene and attention-deficit hyperactivity disorder. Am J Med Genet 2002; 114:255-259. (Pubitemid 34258847)
24. Rippel CA, Kobets AJ, Yoon DY, Williams PN, Shugart YY, Bridges DD, et al. Norepinephrine transporter polymorphisms in Tourette syndrome with and without attention deficit hyperactivity disorder: no evidence for significant association. Psychiatr Genet 2006; 16:179-180. (Pubitemid 44401253)
25. Huang SY, Lu RB, Ma KH, Shy MJ, Lin WW. Norepinephrine transporter polymorphisms T-182C and G1287A are not associated with alcohol dependence and its clinical subgroups. Drug Alcohol Depend 2008; 92:20-26.
26. Samochowiec J, Kucharska-Mazur J, Kaminski R, Smolka M, Rommelschpacher H, Wernicke C, et al. Norepinephrine transporter gene polymorphism is not associated with susceptibility to alcohol dependence. Psychiatry Res 2002; 111:229-233.
27. Kim CH, Waldman ID, Blakely RD, Kim KS. Functional gene variation in the human norepinephrine transporter: association with attention deficit hyperactivity disorder. Ann N Y Acad Sci 2008; 1129:256-260. (Pubitemid 351990292)
28. Suzuki A, Matsumoto Y, Ishii G, Oshino S, Goto K, Otani K. No association between the -3081A/T polymorphism in the norepinephrine transporter gene promoter and personality traits in healthy subjects. Neurosci Lett 2007; 425:192-194. (Pubitemid 47418365)
29. Lee BC, Yang JW, Lee SH, Kim SH, Joe SH, Jung IK, et al. An interaction between the norepinephrine transporter and monoamine oxidase A polymorphisms, and novelty-seeking personality traits in Korean females. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:238-242.
30. Ham BJ, Choi MJ, Lee HJ, Kang RH, Lee MS. Reward dependence is related to norepinephrine transporter T-182C gene polymorphism in a Korean population. Psychiatr Genet 2005; 15:145-147.
31. Tsai SJ, Wang YC, Hong CJ. Norepinephrine transporter and alpha(2c) adrenoceptor allelic variants and personality factors. Am J Med Genet 2002; 114:649-651.
32. Samochowiec J, Kucharska-Mazur J, Rybakowski F, Ostapowicz A, Horodnicki J, Rozpara M, et al. Norepinephrine transporter polymorphism and personality trait of reward dependence in male alcoholics. Pharmacopsychiatry 2002; 35:195-196.
33. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35:837-844. (Pubitemid 9076798)
34. Merikangas KR, Stevens DE, Fenton B, Stolar M, O'Malley S, Woods SW, et al. Co-morbidity and familial aggregation of alcoholism and anxiety disorders. Psychol Med 1998; 28:773-788. (Pubitemid 28393558)
35. American Psychiatric Association. Diagnostic and statistical manua0000l of mental disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994.
36. Huang SY, Lin WW, Ko HC, Lee JF, Wang TJ, Chou YH, et al. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 2004; 28:374-384.
37. Dlugos AM, Hamidovic A, Palmer AA, de Wit H. Further evidence of association between amphetamine response and SLC6A2 gene variants. Psychopharmacology (Berl) 2009; 206:501-511.
38. Belfer I, Phillips G, Taubman J, Hipp H, Lipsky RH, Enoch MA, et al. Haplotype architecture of the norepinephrine transporter gene SLC6A2 in four populations. J Hum Genet 2004; 49:232-245. (Pubitemid 38856015)
39. Kim JW, Biederman J, McGrath CL, Doyle AE, Mick E, Fagerness J, et al. Further evidence of association between two NET singlenucleotide polymorphisms with ADHD. Mol Psychiatry 2008; 13:624-630. (Pubitemid 351704937)
40. Chen WJ, Chen HM, Chen CC, Yu WY, Cheng AT. Cloninger's Tridimensional Personality Questionnaire: psychometric properties and construct validity in Taiwanese adults. Compr Psychiatry 2002; 43:158-166. (Pubitemid 34205459)
41. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265. (Pubitemid 40202029)
42. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002; 296:2225-2229. (Pubitemid 34680308)
43. Cho SC, Kim JW, Kim BN, Hwang JW, Park M, Kim SA, et al. No evidence of an association between norepinephrine transporter gene polymorphisms and attention deficit hyperactivity disorder: a family-based and case-control association study in a Korean sample. Neuropsychobiology 2008; 57:131-138.
44. Peter Z, Rolf E, Thomas CB, Georg J, Thomas F, Florian Ml-S, et al. Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression. Neuropsychopharmacology 2002; 26:489.
45. Ding YS, Singhal T, Planeta-Wilson B, Gallezot JD, Nabulsi N, Labaree D, et al. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT. Synapse 2010; 64:30-38.
46. Kidd KK. Associations of disease with genetic markers: deja vu all over again. Am J Med Genet 1993; 48:71-73. (Pubitemid 23215049)
47. Chiang SC, Chan HY, Chang YY, Sun HJ, Chen WJ, Chen CK. Psychiatric comorbidity and gender difference among treatment-seeking heroin abusers in Taiwan. Psychiatry Clin Neurosci 2007; 61:105-111. (Pubitemid 46089414)
48. Chen J, Zheng H, Bei JX, Sun L, Jia WH, Li T, et al. Genetic structure of the Han Chinese population revealed by genome-wide SNP variation. Am J Hum Genet 2009; 85:775-785.
49. Stram DO. Tag SNP selection for association studies. Genet Epidemiol 2004; 27:365-374. (Pubitemid 39602320)
50. Moldovanova I, Schroeder C, Jacob G, Hiemke C, Diedrich A, Luft FC, et al. Hormonal influences on cardiovascular norepinephrine transporter responses in healthy women. Hypertension 2008; 51:1203-1209. (Pubitemid 351398983)
51. Schroeder C, Adams F, Boschmann M, Tank J, Haertter S, Diedrich A, et al. Phenotypical evidence for a gender difference in cardiac norepinephrine transporter function. Am J Physiol Regul Integr Comp Physiol 2004; 286: R851-R856. (Pubitemid 38506830)
52. El Rawas R, Thiriet N, Lardeux V, Jaber M, Solinas M. Environmental enrichment decreases the rewarding but not the activating effects of heroin. Psychopharmacology (Berl) 2008; 203:561-570.